Literature DB >> 30312551

Cystic Fibrosis: Emerging Understanding and Therapies.

Michael M Rey1, Michael P Bonk1, Denis Hadjiliadis1.   

Abstract

Cystic fibrosis (CF) is the most common life-limiting genetic disease in Caucasian patients. Continued advances have led to improved survival, and adults with CF now outnumber children. As our understanding of the disease improves, new therapies have emerged that improve the basic defect, enabling patient-specific treatment and improved outcomes. However, recurrent exacerbations continue to lead to morbidity and mortality, and new pathogens have been identified that may lead to worse outcomes. In addition, new complications, such as CF-related diabetes and increased risk of gastrointestinal cancers, are creating new challenges in management. For patients with end-stage disease, lung transplantation has remained one of the few treatment options, but challenges in identifying the most appropriate patients remain.

Entities:  

Keywords:  CF exacerbations; CF-related diabetes; CFTR modification; cystic fibrosis; lung transplantation

Year:  2018        PMID: 30312551     DOI: 10.1146/annurev-med-112717-094536

Source DB:  PubMed          Journal:  Annu Rev Med        ISSN: 0066-4219            Impact factor:   13.739


  6 in total

1.  Aerosolized drug-loaded nanoparticles targeting migration inhibitory factors inhibit Pseudomonas aeruginosa-induced inflammation and biofilm formation.

Authors:  Mohammad Doroudian; Andrew O'Neill; Ciaran O'Reilly; Aisling Tynan; Leona Mawhinney; Aoife McElroy; Shanice S Webster; Ronan MacLoughlin; Yuri Volkov; Michelle E Armstrong; George A O'Toole; Adriele Prina-Mello; Seamas C Donnelly
Journal:  Nanomedicine (Lond)       Date:  2020-11-26       Impact factor: 5.307

2.  Cyclic Peptidyl Inhibitors against CAL/CFTR Interaction for Treatment of Cystic Fibrosis.

Authors:  Patrick G Dougherty; Jack H Wellmerling; Amritendu Koley; Jessica K Lukowski; Amanda B Hummon; Estelle Cormet-Boyaka; Dehua Pei
Journal:  J Med Chem       Date:  2020-12-14       Impact factor: 7.446

3.  A Peculiar Case of Pneumonia due to Mycoplasma pneumoniae in a Child with Cystic Fibrosis and Sensibilization to Aspergillus fumigatus.

Authors:  Laura Peccini; Serena Pennoni; Valeria Mencarini; Marco Saponara; Nicola Palladino; Nicola Principi; Guido Pennoni; Susanna Esposito
Journal:  Pathogens       Date:  2019-12-22

4.  Racially equitable diagnosis of cystic fibrosis using next-generation DNA sequencing: a case report.

Authors:  Bennett O V Shum; Glenn Bennett; Akash Navilebasappa; R Kishore Kumar
Journal:  BMC Pediatr       Date:  2021-03-31       Impact factor: 2.125

Review 5.  Intestinal Inflammation and Alterations in the Gut Microbiota in Cystic Fibrosis: A Review of the Current Evidence, Pathophysiology and Future Directions.

Authors:  Rachel Y Tam; Josie M van Dorst; Isabelle McKay; Michael Coffey; Chee Y Ooi
Journal:  J Clin Med       Date:  2022-01-27       Impact factor: 4.241

6.  CFTR dysregulation drives active selection of the gut microbiome.

Authors:  Stacey M Meeker; Kevin S Mears; Naseer Sangwan; Mitchell J Brittnacher; Eli J Weiss; Piper M Treuting; Nicholas Tolley; Christopher E Pope; Kyle R Hager; Anh T Vo; Jisun Paik; Charles W Frevert; Hillary S Hayden; Lucas R Hoffman; Samuel I Miller; Adeline M Hajjar
Journal:  PLoS Pathog       Date:  2020-01-21       Impact factor: 6.823

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.